The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Biotech stocks saw modest gains this week, with earnings providing a boost even as clinical trial results elicited a mixed reaction.

Eli Lilly And Co LLY, Vertex Pharmaceuticals Incorporated VRTX and Gilead Sciences, Inc. GILD are among some prominent biotechs that reported solid results and offered optimistic assessments for thenear-to-medium term. 

Looking ahead to the upcoming week, biotech investors should watch for the following catalytic events. 


  • Global Experts Meeting On Diabetes, Hypertension & Metabolic Syndrome: July 30-31 in Melbourne, Australia.
  • 8th International Conference on Geriatrics Gerontology & Palliative Nursing: July 30-31 in Barcelona, Spain.
  • International Pan Pacific Conference of ART & Perinatology: Aug. 3-5 in Las Vegas.


FDA is set to announce its verdict on Progenics Pharmaceuticals, Inc. PGNX's rare neuroendocrine tumor treatment candidate Azedra on Sunday, July 30.

Neurocrine Biosciences, Inc. NBIX and AbbVie Inc ABBV await the FDA's ruling on Elagolix for endometriosis-associated pain. Based on the three-month extension in the review period announced by the FDA on April 10, the decision could come in July or early August.

See Also: Tricida Post-IPO Run-up Makes Goldman Wary



  • Tandem Diabetes Care Inc TNDM (after the close)
  • GenMark Diagnostics, Inc GNMK (after the close)
  • Lexicon Pharmaceuticals, Inc. LXRX (before the open)


  • Pulse Biosciences Inc PLSE (after the close)
  • Neurocrine Biosciences, Inc. NBIX (after the close)
  • NewLink Genetics Corp NLNK (after the close)
  • Incyte Corporation INCY (before the open)
  • Medpace Holdings Inc MEDP (before the open)
  • Hologic, Inc. HOLX (after the close)
  • Pfizer Inc. PFE (before the open)
  • NuVasive, Inc. NUVA (after the close)
  • Qiagen NV QGEN
  • Illumina, Inc. ILMN (after the close)


  • Conatus Pharmaceuticals Inc CNAT (after the close)
  • Amarin Corporation plc (ADR) AMRN (before the open)
  • ArQule, Inc. ARQL (before the open)
  • AtriCure Inc. ATRC (after the close)
  • AxoGen, Inc AXGN
  • Blueprint Medicines Corp BPMC (before the open)
  • EXACT Sciences Corporation EXAS (after the close)
  • Vanda Pharmaceuticals Inc. VNDA (after the close)
  • Globus Medical Inc GMED (after the close)
  • IDEXX Laboratories, Inc. IDXX (before the open)
  • Clovis Oncology Inc CLVS (after the close)
  • DURECT Corporation DRRX (after the close)
  • Exelixis, Inc. EXEL (after the close)


  • Genomic Health, Inc. GHDX (after the close)
  • Obalon Therapeutics Inc OBLN (before the open)
  • Acceleron Pharma Inc XLRN (after the close)
  • Insmed Incorporated INSM (before the open)
  • Seres Therapeutics Inc MCRB (before the open)
  • Curis, Inc. CRIS (before the open)
  • Acorda Therapeutics Inc ACOR (before the open)
  • AcelRx Pharmaceuticals Inc ACRX (after the close)
  • Agios Pharmaceuticals Inc AGIO (before the open)
  • Becton Dickinson and Co BDX (before the open)
  • Arbutus Biopharma Corp ABUS (after the close)
  • Emergent Biosolutions Inc EBS (after the close)
  • T2 Biosystems Inc TTOO (after the close)
  • BioMarin Pharmaceutical Inc. BMRN (after the close)
  • Pacific Biosciences of California PACB (after the close)
  • Nevro Corp NVRO (after the close)
  • Cerus Corporation CERS (after the close)
  • TESARO Inc TSRO (after the close)
  • Regeneron Pharmaceuticals Inc REGN (before the open)
  • Revance Therapeutics Inc RVNC (after the close)
  • Pacira Pharmaceuticals Inc PCRX (before the open)
  • Zoetis Inc ZTS (before the open)
  • ResMed Inc. RMD
  • Insulet Corporation PODD (after the close)
  • Glaukos Corp GKOS (after the close)
  • Repligen Corporation RGEN (before the open)
  • Epizyme Inc EPZM (before the open)
  • Aratana Therapeutics Inc PETX


Bionano Genomics, an instrumentation company operating in the genome analysis space, is proposing to offer 3.35 million shares in an IPO, with the price range estimated between $8 and $10. The company intends to list its shares on the Nasdaq under the ticker symbol "BNGO."

Posted In: BiotechEarningsNewsHealth CarePreviewsFDATop StoriesTrading IdeasGeneral